News - Research

Filter

Current filters:

Research

Popular Filters

60 to 84 of 2362 results

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

25-03-2014

US pharma behemoth Pfizer says that PROFILE 1014, a Phase III study of anaplastic lymphoma kinase (ALK)…

OncologyPfizerPharmaceuticalResearchXalkori

37 new medicines in development for Parkinson’s disease by PhRMA firms

25-03-2014

The USA’s biopharmaceutical research companies currently are developing 37 innovative new medicines…

NeurologicalNorth AmericaPharmaceuticalResearchUSA

Next-generation therapeutics for infectious diseases conquer the global spotlight

25-03-2014

The available antivirals for commonly occurring infections such as respiratory syncytial virus (RSV)…

Antibiotics and Infectious diseasesPharmaceuticalResearch

AstraZeneca unit debuts new open innovation platform for partnering programs

25-03-2014

Anglo-Swedish drug major AstraZeneca’s IMED Biotech unit has launched a dedicated web site to support…

AstraZenecaBiotechnologyResearch

Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis

25-03-2014

New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis

24-03-2014

US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…

apremilastBiotechnologyCelgeneDermatologicalsOtezlaResearch

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis

24-03-2014

US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…

DermatologicalsEnbrelPfizerPharmaceuticalResearchtofacitinibXeljanz

Use of mood stabilizing drug linked with reduced risk of developing head and neck cancer

24-03-2014

A new study indicates that a commonly used mood stabilizing drug may help prevent head and neck cancer.…

NeurologicalOncologyPharmaceuticalResearchValproic Acid

India urged to take action on unregulated tuberculosis drug sales

23-03-2014

Although cases of tuberculosis are dropping in Europe, as is the incidence in the USA, an extremely slower…

Antibiotics and Infectious diseasesAsia-PacificHealthcareIndiaPharmaceuticalResearch

Improving awareness of unfashionable cancers

Improving awareness of unfashionable cancers

21-03-2014

Here's our take on the week's top stories.

OncologyPharmaceuticalResearch

Positive mid-stage results for Forest Labs and Gedeon Richter’s cariprazine in MDD

21-03-2014

US drugmaker Forest Laboratories and Gedeon Richter, Hungary’s largest pharma company, have released…

cariprazineForest LaboratoriesGedeon RichterNeurologicalPharmaceuticalResearch

Phase II trial shows simvastatin slows progression of multiple sclerosis

21-03-2014

Simvastatin, the active ingredient of Merck & Co’s (NYSE: MRK) now off patent cholesterol-lowerer Zocor,…

Merck & CoNeurologicalPharmaceuticalResearchSimvastatinUK

Report: New drugs needed for prostate cancer as incidents rise

Report: New drugs needed for prostate cancer as incidents rise

21-03-2014

Over half a million cases of prostate cancer will be diagnosed worldwide in 2014 leading to a demand…

EuropeJohnson & JohnsonOncologyPharmaceuticalResearchUSAXtandiZytiga

US FDA eases clinical hold on Geron’s imetelstat

US FDA eases clinical hold on Geron’s imetelstat

21-03-2014

There was a touch of good news yesterday for Geron Corp, after the US Food and Drug Administrated partially…

BiotechnologyGeron CorpimetelstatNorth AmericaOncologyRegulationResearchUSA

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

20-03-2014

US biotech company Emmaus Life Sciences, which focuses on orphan diseases, has announced preliminary…

BiotechnologyHematologyResearchUSA

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

20-03-2014

Following an Independent Data Monitoring Committee recommendation based on positive efficacy, a Johnson…

Invega SustennaJanssenJohnson & JohnsonNeurologicalpaliperidone palmitatePharmaceuticalResearch

New US guidelines could see 12.8 million more patients prescribed statins

New US guidelines could see 12.8 million more patients prescribed statins

20-03-2014

New US guidelines regarding those patients who are prescribed statins to prevent cardiovascular disease…

Cardio-vascularHealthcarePharmaceuticalResearchUSA

Brazil Senate discusses pathways for advancement of clinical research

Brazil Senate discusses pathways for advancement of clinical research

20-03-2014

The Brazilian Senate's Social Affairs Committee (CAS) held a hearing on March 18 to debate the progress…

BrazilPharmaceuticalRegulationResearch

Report: Action must be taken to improve treatments for bladder cancer

Report: Action must be taken to improve treatments for bladder cancer

20-03-2014

There is an urgent need for new drugs for bladder cancer, according to a new paper published in European…

OncologyPharmaceuticalResearchUK

Japan’s Eisai joins forces with UK researchers on tropical disease research

Japan’s Eisai joins forces with UK researchers on tropical disease research

20-03-2014

Japanese drug major Eisai has entered a collaboration with the UK’s Liverpool School of Tropical Medicine…

EisaiPharmaceuticalResearchTropical diseases

EMA launches adaptive licensing pilot project to improve access to medicines

EMA launches adaptive licensing pilot project to improve access to medicines

20-03-2014

The European Medicines Agency is inviting companies to participate in its adaptive licensing pilot project…

EuropePharmaceuticalResearch

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

20-03-2014

There was another setback for UK pharma giant GlaxoSmithKline with its MAGE-A3 antigen specific cancer…

AgenusGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearch

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

19-03-2014

Danish insulin giant Novo Nordisk says it has completed the pathfinderT2, the first Phase III trial with…

HematologyN8-GPNovo NordiskPharmaceuticalResearchturoctocog alfa

Promising mid-stage results for Prosensa’s drisapersen in DMD boys

19-03-2014

Shares of Dutch biotech firm Prosensa Holding rose 3.85% to $7.02 after the firm reported encouraging…

BiotechnologydrisapersenGlaxoSmithKlineProsensaRare diseasesResearch

60 to 84 of 2362 results

Back to top